MX2019005125A - Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. - Google Patents

Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular.

Info

Publication number
MX2019005125A
MX2019005125A MX2019005125A MX2019005125A MX2019005125A MX 2019005125 A MX2019005125 A MX 2019005125A MX 2019005125 A MX2019005125 A MX 2019005125A MX 2019005125 A MX2019005125 A MX 2019005125A MX 2019005125 A MX2019005125 A MX 2019005125A
Authority
MX
Mexico
Prior art keywords
isoform
cell
immunologically
agent
antibody
Prior art date
Application number
MX2019005125A
Other languages
English (en)
Inventor
Recher Mike
Jeker Lukas
KORNETE Mara
BORDOLI SCHWEDE Lorenza
SCHWEDE Torsten
Lepore Rosalba
MATTER MARONE Romina
Original Assignee
Univ Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/059799 external-priority patent/WO2017186718A1/en
Application filed by Univ Basel filed Critical Univ Basel
Publication of MX2019005125A publication Critical patent/MX2019005125A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70589—CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)

Abstract

La invención se refiere a una célula de mamífero, particularmente una célula humana, que expresa una primera isoforma de una proteína de superficie, en donde la primera isoforma es funcionalmente indistinguible, pero inmunológicamente distinguible de una segunda isoforma, para uso en un tratamiento médico de un paciente que tiene células que expresan la segunda isoforma de la proteína de superficie; la invención se refiere además a un agente seleccionado de 1) un compuesto que comprende, o consiste de, un anticuerpo o molécula tipo anticuerpo y 2) una célula efectora inmune que porta una molécula tipo anticuerpo o una célula efectora inmune que porta un receptor de antígeno quimérico, para uso en un método de tratamiento de una condición medica, en donde el agente es específicamente reactivo a cualquiera de una primera o una segunda isoforma de una proteína de superficie, en donde la primera isoforma es funcionalmente indistinguible, pero inmunológicamente distinguible de la segunda isoforma, y en donde el agente se administra para cortar una célula que porta la isoforma a la que es reactivo el agente.
MX2019005125A 2016-11-02 2017-10-30 Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular. MX2019005125A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16196860 2016-11-02
EP16196858 2016-11-02
PCT/EP2017/059799 WO2017186718A1 (en) 2016-04-25 2017-04-25 Allele editing and applications thereof
EP17197820 2017-10-23
PCT/EP2017/077826 WO2018083071A1 (en) 2016-11-02 2017-10-30 Immunologically discernible cell surface variants for use in cell therapy

Publications (1)

Publication Number Publication Date
MX2019005125A true MX2019005125A (es) 2019-08-29

Family

ID=62075802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005125A MX2019005125A (es) 2016-11-02 2017-10-30 Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular.

Country Status (20)

Country Link
US (1) US20190365806A1 (es)
EP (2) EP3535392B1 (es)
JP (2) JP7305539B2 (es)
KR (2) KR20240043810A (es)
CN (1) CN110191948A (es)
AU (1) AU2017355218B2 (es)
BR (1) BR112019008975A2 (es)
CA (1) CA3041582A1 (es)
DK (1) DK3535392T3 (es)
ES (1) ES2977969T3 (es)
FI (1) FI3535392T3 (es)
HR (1) HRP20240842T1 (es)
IL (1) IL266362B2 (es)
LT (1) LT3535392T (es)
MX (1) MX2019005125A (es)
PL (1) PL3535392T3 (es)
SG (1) SG11201903454VA (es)
SI (1) SI3535392T1 (es)
WO (1) WO2018083071A1 (es)
ZA (1) ZA201902426B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016337525B2 (en) 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
US11499168B2 (en) 2016-04-25 2022-11-15 Universitat Basel Allele editing and applications thereof
EP3583218A4 (en) * 2017-02-17 2020-12-30 Purdue Research Foundation TARGETED ACTIVE SUBSTANCE RELEASE ON LIGAND PAYLOAD BASIS FOR CELL THERAPY
CA3054808A1 (en) * 2017-02-28 2018-09-07 Vor Biopharma, Inc. Compositions and methods for inhibition lineage specific proteins
US11464803B2 (en) 2017-11-14 2022-10-11 Arcellx, Inc. D-domain containing polypeptides and uses thereof
KR20200087176A (ko) * 2017-11-14 2020-07-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
JP7285267B2 (ja) 2017-11-14 2023-06-01 アーセルクス インコーポレイテッド Ｄドメイン含有ポリペプチドおよびその使用
GB2589246A (en) 2018-05-16 2021-05-26 Synthego Corp Methods and systems for guide RNA design and use
AU2019295855A1 (en) * 2018-06-29 2021-01-28 City Of Hope CD6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
JP2022520138A (ja) 2018-08-28 2022-03-29 ブイオーアール バイオファーマ インコーポレーテッド 遺伝子操作された造血幹細胞およびそれらの使用
EP3844274A1 (en) * 2018-08-28 2021-07-07 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
KR102689877B1 (ko) * 2019-11-28 2024-08-01 주식회사 센트릭스바이오 CD300c 항원 또는 그의 수용체에 특이적으로 결합하는 키메라 항원 수용체
US20230076643A1 (en) * 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
KR102347797B1 (ko) * 2020-03-03 2022-01-07 한국과학기술원 대식세포 세포 표면 항원 및 이의 다양한 용도
CA3175860A1 (en) * 2020-03-27 2021-09-30 The Trustees Of Indiana University Immunotherapeutic targets in multiple myeloma and methods for their identification
US20240024476A1 (en) * 2021-01-07 2024-01-25 Innovative Cellular Therapeutics Holdings, Ltd. CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor
CN112852875B (zh) * 2021-02-26 2022-10-21 福建省立医院 示踪肿瘤T淋巴细胞浸润的CD3e转基因小鼠模型的构建方法
CN113125755A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的9抗体试剂盒及应用
CN113125718A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的45抗体试剂盒及应用
CN113125754A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的23抗体试剂盒及应用
CN113109575A (zh) * 2021-04-16 2021-07-13 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的40抗体试剂盒及应用
CN113125733A (zh) * 2021-04-16 2021-07-16 浙江普罗亭健康科技有限公司 一种用于监测人体免疫状态的42抗体试剂盒及应用
AU2021447099A1 (en) * 2021-05-27 2023-02-16 Cas Lamvac (Guangzhou) Biomedical Technology Co., Ltd. Method and kit for analyzing phenotype and function of CD303
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
JP2024528202A (ja) 2021-08-02 2024-07-26 ブイオーアール バイオファーマ インコーポレーテッド 遺伝子修飾のための組成物及び方法
EP4380693A1 (en) 2021-08-06 2024-06-12 Universität Basel Discernible cell surface protein variants for use in cell therapy
WO2023111311A1 (en) 2021-12-16 2023-06-22 Universität Basel Discernible cell surface protein variants of cd117 for use in cell therapy
CA3240875A1 (en) 2021-12-23 2023-06-29 Stefanie Urlinger Discernible cell surface protein variants of cd45 for use in cell therapy
CN114292830B (zh) * 2021-12-31 2024-05-03 复旦大学 蛋白SaCas9的抗原表位及其在基因编辑中的应用
WO2024015925A2 (en) * 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
WO2024097131A1 (en) * 2022-11-04 2024-05-10 The Board Of Trustees Of The Leland Stanford Junior University Rebalancing the immune system through depletion of myeloid-biased hematopoietic stem cells
WO2024208836A1 (en) 2023-04-03 2024-10-10 Universität Basel Discernible cell surface protein variants of cd33 for use in cell therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002240745A1 (en) * 2001-03-07 2002-09-19 Andre Schuh Diagnosis and treatment of blood disorders
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
EP3255061B1 (en) * 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
WO2009023816A1 (en) * 2007-08-15 2009-02-19 Emory University Methods of making monoclonal antibodies using fusion- peptide epitope adoptive transfer (f-peat) technology
BRPI0923422A2 (pt) * 2008-12-12 2016-06-21 Univ Tokyo promotor de reconstituição imunológica ou agente profilático para infecções cada um dos quais mantém o efeito enxerto-versus-tumor "
PL2928496T3 (pl) * 2012-12-06 2020-04-30 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu w oparciu o CRISPR
PT2970487T (pt) * 2013-03-12 2020-06-17 Molecular Templates Inc Proteínas citotóxicas compreendendo regiões de ligação de direcionamento para células e regiões de subunidades de toxina a shiga para a morte seletiva de tipos específicos de células
AU2014274916B2 (en) * 2013-06-05 2019-10-31 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
AU2014284079B2 (en) * 2013-06-17 2019-05-23 Chu Sainte-Justine A method of increasing GiPCR signalization in the cells of a scoliotic subject
WO2016014837A1 (en) * 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
ES2692206T3 (es) * 2014-11-26 2018-11-30 Miltenyi Biotec Gmbh Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades
EA201891092A1 (ru) * 2015-11-04 2018-10-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способы и композиции для редактирования генов в гемопоэтических стволовых клетках
US11136597B2 (en) * 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
IL313038A (en) * 2016-03-14 2024-07-01 Editas Medicine Inc Methods and preparations related to CRISPR/CAS - for the treatment of diseases in the hemoglobin cell
US11499168B2 (en) * 2016-04-25 2022-11-15 Universitat Basel Allele editing and applications thereof

Also Published As

Publication number Publication date
RU2019116783A (ru) 2020-12-03
SG11201903454VA (en) 2019-05-30
JP7305539B2 (ja) 2023-07-10
LT3535392T (lt) 2024-04-25
CN110191948A (zh) 2019-08-30
IL266362B1 (en) 2024-03-01
WO2018083071A1 (en) 2018-05-11
IL266362A (en) 2019-06-30
EP4360639A2 (en) 2024-05-01
ES2977969T3 (es) 2024-09-03
JP2019533450A (ja) 2019-11-21
AU2017355218A1 (en) 2019-05-02
EP3535392B1 (en) 2024-03-27
PL3535392T3 (pl) 2024-07-29
AU2017355218B2 (en) 2024-02-22
IL266362B2 (en) 2024-07-01
SI3535392T1 (sl) 2024-07-31
RU2019116783A3 (es) 2021-03-05
KR20240043810A (ko) 2024-04-03
JP2023126852A (ja) 2023-09-12
EP4360639A3 (en) 2024-07-17
FI3535392T3 (fi) 2024-05-23
DK3535392T3 (da) 2024-04-22
ZA201902426B (en) 2020-10-28
BR112019008975A2 (pt) 2019-07-09
KR20190072639A (ko) 2019-06-25
EP3535392A1 (en) 2019-09-11
CA3041582A1 (en) 2018-05-11
HRP20240842T1 (hr) 2024-10-11
US20190365806A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
MX2019005125A (es) Variantes de superficie celular discernibles inmunologicamente para uso en terapia celular.
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
MX2024005027A (es) Anticuerpos de union a cd3.
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
JP2017538669A5 (es)
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014183066A3 (en) Protein modification of living cells using sortase
IN2015KN00350A (es)
WO2013088148A3 (en) Method of treatment employing therapeutic t cell product from mobilised donors
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
EP2068929A4 (en) METHOD OF DETECTING AND TREATING SKIN DISORDERS
Lee et al. A rabbit model of fat graft recipient site preconditioning using external negative pressure
MX2018009499A (es) Anticuerpos monoclonales especificos de egfl6 y metodos de su uso.
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
MX2023008115A (es) Terapia con receptores quiméricos.
NZ735720A (en) Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy
MX2018011169A (es) Metodo para prevenir la enfermedad del injerto contra huesped.
WO2018060528A3 (en) Therapeutic protein
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
EA201792294A1 (ru) Комбинированное лечение (варианты) с применением серибантумаба
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
WO2022238963A3 (en) Genetically engineered immune cells targeting cd70 for use in treating solid tumors